Estrogen administration to women who are breastfeeding has been shown to decrease the quantity and quality of the milk. Estrogens are not indicated for the prevention of postpartum breast engorgement.
A Women's Health Initiative (WHI) estrogen alone study reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50–79 years of age) and an increased risk of developing probable dementia in postmenopausal women over 65 years of age.
Large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. Estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce gynecomastia.
- TRADE NAMES: Cyren A; Destrol; Estinyl; Estrace (Warner Chilcott); Estraderm (Novartis); Estratab (Solvay); Estroject; Estronol; Estrovis; Gynogen; Menest (Monarch); Ogen (Pfizer); Premarin (Wyeth); Stilphostrol; Theelin
- INDICATIONS: Menopausal symptoms, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, postmenopausal osteoporosis
- CLASS: Estrogen
- HALF-LIFE: N/A
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acarbose, Acebutolol, Alfuzosin, Amitriptyline, Anastrozole, Aprepitant, Atazanavir, Beclomethasone, Betamethasone, Captopril, Cilazapril, Darunavir, Enalapril, Flunisolide, Fosinopril, Hydrocortisone, Indinavir, Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Lisinopril, Metformin, Minocycline, Nelfinavir, Olmesartan, Oxtriphylline, Penicillin G, Penicillin V, Prednisone, Quinapril, Ramipril, Saxagliptin, Sitagliptin, Somatropin, Terbinafine, Tipranavir, Trandolapril, Triamcinolone, Ursodiol, Voriconazole
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
